| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Pedro A Valiente | Q56599893 |
| Alejandro Gil-Ley | Q86709485 | ||
| Tirso Pons | Q40459651 | ||
| P2093 | author name string | Pedro G Pascutti | |
| Alejandro Gil L | |||
| P2860 | cites work | That Was Then But This Is Now: Malaria Research in the Time of an Eradication Agenda | Q22061808 |
| Genome sequence of the human malaria parasite Plasmodium falciparum | Q22122524 | ||
| Recombinant expression and enzymatic subsite characterization of plasmepsin 4 from the four Plasmodium species infecting man. | Q45002397 | ||
| Critical roles for the digestive vacuole plasmepsins of Plasmodium falciparum in vacuolar function | Q45011108 | ||
| Genetic disruption of the Plasmodium falciparum digestive vacuole plasmepsins demonstrates their functional redundancy | Q45112972 | ||
| The role of Plasmodium falciparum food vacuole plasmepsins | Q45129812 | ||
| Computational prediction of structure, substrate binding mode, mechanism, and rate for a malaria protease with a novel type of active site | Q45150900 | ||
| Search for substrate-based inhibitors fitting the S2' space of malarial aspartic protease plasmepsin II. | Q45165701 | ||
| Computer-aided design and synthesis of nonpeptidic plasmepsin II and IV inhibitors | Q46408285 | ||
| X-ray structure of plasmepsin II complexed with a potent achiral inhibitor | Q46445865 | ||
| Structural and active site analysis of plasmepsins of Plasmodium falciparum: potential anti-malarial targets | Q46767937 | ||
| Protein-ligand binding free energy estimation using molecular mechanics and continuum electrostatics. Application to HIV-1 protease inhibitors | Q47655078 | ||
| Computation of affinity and selectivity: binding of 2,4-diaminopteridine and 2,4-diaminoquinazoline inhibitors to dihydrofolate reductases | Q47742338 | ||
| Screening aspartyl proteases with combinatorial libraries. | Q47829651 | ||
| Sugar recognition by a glucose/galactose receptor. Evaluation of binding energetics from molecular dynamics simulations. | Q50143963 | ||
| Can we trust docking results? Evaluation of seven commonly used programs on PDBbind database. | Q51664708 | ||
| Alternative to consensus scoring--a new approach toward the qualitative combination of docking algorithms. | Q51915270 | ||
| Knowledge-based scoring function to predict protein-ligand interactions. | Q52083236 | ||
| Ligand solvation in molecular docking. | Q52214239 | ||
| A general and fast scoring function for protein-ligand interactions: a simplified potential approach. | Q52222006 | ||
| Empirical scoring functions. II. The testing of an empirical scoring function for the prediction of ligand-receptor binding affinities and the use of Bayesian regression to improve the quality of the model. | Q52230454 | ||
| A fast flexible docking method using an incremental construction algorithm. | Q52298930 | ||
| Estimation of binding free energies for HIV proteinase inhibitors by molecular dynamics simulations. | Q52324255 | ||
| AMBER: Assisted model building with energy refinement. A general program for modeling molecules and their interactions | Q53341450 | ||
| Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. | Q53678858 | ||
| An innovative application of the "flexible" GRID/PCA computational method: study of differences in selectivity between PGAs from Escherichia coli and a Providentia rettgeri mutant. | Q54501737 | ||
| Mapping selectivity and specificity of active site of plasmepsins from Plasmodium falciparum using molecular interaction field approach | Q56435972 | ||
| Kinetic analysis of plasmepsins I and II aspartic proteases of the Plasmodium falciparum digestive vacuole | Q71622814 | ||
| Binding free energy calculations for P450cam-substrate complexes | Q71623180 | ||
| A new method for predicting binding affinity in computer-aided drug design | Q72408636 | ||
| Ligand binding affinity prediction by linear interaction energy methods | Q74505232 | ||
| Hemoglobin-degrading plasmepsin II is active as a monomer | Q79240095 | ||
| Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II | Q80075132 | ||
| An iterative knowledge-based scoring function to predict protein-ligand interactions: II. Validation of the scoring function | Q80287324 | ||
| Improving the Accuracy of the Linear Interaction Energy Method for Solvation Free Energies | Q86855672 | ||
| Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria | Q24538763 | ||
| Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum | Q24597864 | ||
| Plasmepsin V licenses Plasmodium proteins for export into the host erythrocyte | Q24644157 | ||
| DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases | Q27231136 | ||
| Structures of Ser205 mutant plasmepsin II from Plasmodium falciparum at 1.8 A in complex with the inhibitors rs367 and rs370 | Q27640033 | ||
| Novel uncomplexed and complexed structures of plasmepsin II, an aspartic protease from Plasmodium falciparum | Q27640611 | ||
| Recombinant Plasmepsin 1 from the Human Malaria Parasite Plasmodium falciparum : Enzymatic Characterization, Active Site Inhibitor Design, and Structural Analysis | Q27654043 | ||
| Crystal Structures of the Histo-Aspartic Protease (HAP) from Plasmodium falciparum | Q27654096 | ||
| A Plasmodium falciparum dipeptidyl aminopeptidase I participates in vacuolar hemoglobin degradation | Q27972584 | ||
| Expression and characterization of the Plasmodium falciparum haemoglobinase falcipain-3 | Q27973740 | ||
| Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine | Q28207735 | ||
| Development and validation of a genetic algorithm for flexible docking | Q28236574 | ||
| Sequence, expression and modeled structure of an aspartic proteinase from the human malaria parasite Plasmodium falciparum | Q28239261 | ||
| Discovery of plasmepsin inhibitors by fragment-based docking and consensus scoring | Q28246329 | ||
| Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy | Q28251042 | ||
| Virtual screening strategies in drug discovery | Q28253252 | ||
| eHiTS: a new fast, exhaustive flexible ligand docking system | Q28253448 | ||
| Hemoglobin degradation in the malaria parasite Plasmodium falciparum: an ordered process in a unique organelle | Q28972254 | ||
| AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility | Q29547658 | ||
| An evolutionary trace method defines binding surfaces common to protein families | Q29615880 | ||
| Improved protein-ligand docking using GOLD | Q29616787 | ||
| Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening | Q29617343 | ||
| Identification and characterization of falcilysin, a metallopeptidase involved in hemoglobin catabolism within the malaria parasite Plasmodium falciparum | Q30042132 | ||
| Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine | Q30042887 | ||
| Hemoglobin degradation in the human malaria pathogen Plasmodium falciparum: a catabolic pathway initiated by a specific aspartic protease | Q30045945 | ||
| FlexE: efficient molecular docking considering protein structure variations. | Q30328164 | ||
| A computational procedure for determining energetically favorable binding sites on biologically important macromolecules | Q30406755 | ||
| Potent, low-molecular-weight non-peptide inhibitors of malarial aspartyl protease plasmepsin II. | Q30672366 | ||
| Sensitivity of an empirical affinity scoring function to changes in receptor-ligand complex conformations | Q30689339 | ||
| Computational analysis of plasmepsin IV bound to an allophenylnorstatine inhibitor. | Q30827566 | ||
| Computational modelling of inhibitor binding to human thrombin | Q30982674 | ||
| Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II devoid of cathepsin D inhibitory activity | Q31034495 | ||
| Structure and mechanism of the pepsin-like family of aspartic peptidases | Q35021899 | ||
| Inhibitors of the Plasmodium falciparum parasite aspartic protease plasmepsin II as potential antimalarial agents | Q35100335 | ||
| Functional expression of falcipain, a Plasmodium falciparum cysteine proteinase, supports its role as a malarial hemoglobinase. | Q35415207 | ||
| Free energy calculations and ligand binding | Q35590736 | ||
| Computational approaches to model ligand selectivity in drug design. | Q36384971 | ||
| Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go. | Q37014096 | ||
| Docking, virtual high throughput screening and in silico fragment-based drug design | Q37296002 | ||
| Current status of malaria chemotherapy and the role of pharmacology in antimalarial drug research and development | Q37587440 | ||
| Scoring functions and their evaluation methods for protein-ligand docking: recent advances and future directions. | Q37781709 | ||
| Building an infrastructure for scientific Grid computing: status and goals of the EGEE project | Q38456632 | ||
| The aspartic proteinase from the rodent parasite Plasmodium berghei as a potential model for plasmepsins from the human malaria parasite, Plasmodium falciparum. | Q38526967 | ||
| Expression and characterisation of plasmepsin I from Plasmodium falciparum | Q38530094 | ||
| Free energy via molecular simulation: applications to chemical and biomolecular systems | Q38648060 | ||
| Role of Plasmodium falciparum digestive vacuole plasmepsins in the specificity and antimalarial mode of action of cysteine and aspartic protease inhibitors | Q39947285 | ||
| Characterization of events preceding the release of malaria parasite from the host red blood cell | Q40398772 | ||
| What determines the van der Waals coefficient beta in the LIE (linear interaction energy) method to estimate binding free energies using molecular dynamics simulations? | Q41607783 | ||
| Characterization of native and recombinant falcipain-2, a principal trophozoite cysteine protease and essential hemoglobinase of Plasmodium falciparum | Q41745894 | ||
| Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities. | Q42550712 | ||
| New parameterization approaches of the LIE method to improve free energy calculations of PlmII-Inhibitors complexes | Q42908159 | ||
| Pyrrolidine derivatives as plasmepsin inhibitors: binding mode analysis assisted by molecular dynamics simulations of a highly flexible protein | Q43180983 | ||
| Predicting functional residues in Plasmodium falciparum plasmepsins by combining sequence and structural analysis with molecular dynamics simulations. | Q43480874 | ||
| Activity and inhibition of plasmepsin IV, a new aspartic proteinase from the malaria parasite, Plasmodium falciparum | Q43923777 | ||
| LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads | Q44114180 | ||
| Plasmepsin inhibitors: design, synthesis, inhibitory studies and crystal structure analysis | Q44244370 | ||
| LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites | Q44247315 | ||
| High-affinity inhibition of a family of Plasmodium falciparum proteases by a designed adaptive inhibitor | Q44511791 | ||
| General model for estimation of the inhibition of protein kinases using Monte Carlo simulations | Q44871650 | ||
| Ligand binding affinities from MD simulations. | Q31080599 | ||
| Trends in virtual combinatorial library design | Q31120448 | ||
| C2-symmetric inhibitors of Plasmodium falciparum plasmepsin II: synthesis and theoretical predictions | Q31151933 | ||
| Plasmepsin 4, the food vacuole aspartic proteinase found in all Plasmodium spp. infecting man. | Q33193846 | ||
| Binding affinity prediction with different force fields: examination of the linear interaction energy method | Q33202843 | ||
| Efficient evaluation of binding free energy using continuum electrostatics solvation | Q33208396 | ||
| Active-site specificity of digestive aspartic peptidases from the four species of Plasmodium that infect humans using chromogenic combinatorial peptide libraries | Q33211575 | ||
| The computer program LUDI: a new method for the de novo design of enzyme inhibitors | Q33214112 | ||
| Synthesis of malarial plasmepsin inhibitors and prediction of binding modes by molecular dynamics simulations | Q33223342 | ||
| Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV. | Q33227803 | ||
| Virtual ligand screening: strategies, perspectives and limitations | Q33247681 | ||
| Plasmepsins as potential targets for new antimalarial therapy | Q33250030 | ||
| The potential of P1 site alterations in peptidomimetic protease inhibitors as suggested by virtual screening and explored by the use of C-C-coupling reagents | Q33253061 | ||
| Inhibitor binding to the plasmepsin IV aspartic protease from Plasmodium falciparum | Q33255678 | ||
| Design of new plasmepsin inhibitors: a virtual high throughput screening approach on the EGEE grid | Q33295426 | ||
| WISDOM-II: screening against multiple targets implicated in malaria using computational grid infrastructures | Q33437882 | ||
| alpha-Substituted norstatines as the transition-state mimic in inhibitors of multiple digestive vacuole malaria aspartic proteases | Q33487551 | ||
| Library screening by fragment-based docking | Q33498543 | ||
| Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds | Q33682916 | ||
| New class of small nonpeptidyl compounds blocks Plasmodium falciparum development in vitro by inhibiting plasmepsins | Q33982942 | ||
| Order and specificity of the Plasmodium falciparum hemoglobin degradation pathway | Q34139669 | ||
| A geometric approach to macromolecule-ligand interactions | Q34280176 | ||
| A method to predict functional residues in proteins | Q34310572 | ||
| Molecular characterization and inhibition of a Plasmodium falciparum aspartic hemoglobinase. | Q34350086 | ||
| Docking and scoring in virtual screening for drug discovery: methods and applications | Q34364227 | ||
| Computer-based de novo design of drug-like molecules | Q34438895 | ||
| Plasmodium falciparum, P. vivax, and P. malariae: a comparison of the active site properties of plasmepsins cloned and expressed from three different species of the malaria parasite | Q34446519 | ||
| Designing non-peptide peptidomimetics in the 21st century: inhibitors targeting conformational ensembles. | Q34503862 | ||
| The linear interaction energy method for predicting ligand binding free energies | Q34506720 | ||
| Plasmodium falciparum cysteine protease falcipain-1 is not essential in erythrocytic stage malaria parasites | Q34514862 | ||
| Further development and validation of empirical scoring functions for structure-based binding affinity prediction | Q34526566 | ||
| Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets. | Q34548661 | ||
| Plasmodium falciparum ensures its amino acid supply with multiple acquisition pathways and redundant proteolytic enzyme systems | Q34645537 | ||
| The integration of genomic and structural information in the development of high affinity plasmepsin inhibitors | Q34999498 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 657483 | |
| P577 | publication date | 2011-07-03 | |
| P1433 | published in | Journal of Tropical Medicine | Q26842862 |
| P1476 | title | Computational perspectives into plasmepsins structure-function relationship: implications to inhibitors design | |
| P478 | volume | 2011 |
| Q56374979 | Deciphering the mechanism of potent peptidomimetic inhibitors targeting plasmepsins - biochemical and structural insights |
| Q40766306 | Flap flexibility amongst plasmepsins I, II, III, IV, and V: Sequence, structural, and molecular dynamics analyses |
| Q37973268 | Microbial and fungal protease inhibitors--current and potential applications |
| Q38109627 | Trafficked Proteins-Druggable in Plasmodium falciparum? |
Search more.